MrMed sees 50% growth in revenue in FY24

CHENNAI: MrMed, an online platform for specialty medicines, on Wednesday, announced its financial growth for the fiscal year 2024. The company has brought down its overall loss by 31% to Rs 1.5 crore.

The company's revenue increased to Rs 24 crore, a 50% growth from FY23. It also a 177% increase in gross margins with total losses reducing by 31% compared to the previous fiscal year. Additionally, the percentage of losses has decreased by 50%.

Devashish Singh, Co-Founder & CEO at MrMed, said in a statement, "We understand the challenges of obtaining timely access to medications while facing serious health issues like cancer, late stage chronic diseases, or viral infections like HIV and hepatitis, and we are dedicated to ensuring they receive the care they need on time. The growth we've experienced this year is not solely about our own success; it signifies our commitment to making a meaningful impact in people's lives, which motivates us every day.”


MrMed aims to make life-saving and speciality medicines more affordable and accessible while enhancing its operational efficiencies.